This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through October 6, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Centene Corporation is a well-diversified, multi-national healthcare company that primarily provides a set of services to the government sponsored healthcare programs. The company serves the under-insured and uninsured individuals through member-focused services. It is also engaged in providing education and outreach programs to inform and assist members in accessing quality, appropriate healthcare services. Centene is now a $100-billion plus enterprise catering healthcare services to more than 24 million members across 50 states. The recent acquisition of WellCare Health leveraged the company’s position as the largest Medicaid managed care organization in the country. The combined entity now has 22 million members. In 2019, the company retained its market-leading position nationwide, serving 1.8 million exchange members across 20 states at the year-end.
All You Need to Know About Centene (CNC) Rating Upgrade to Strong Buy
by Zacks Equity Research
Centene (CNC) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Are Investors Undervaluing Centene (CNC) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Best Value Stock to Buy for Oct. 31st
by Zacks Equity Research
CNC, NWG and UVV made it to the Zacks Rank #1 (Strong Buy) value stocks list on October 31, 2025.
New Strong Buy Stocks for Oct. 31: PMT, NWG, and More
by Zacks Equity Research
PMT, NWG, PAHC, CNC and ACNB have been added to the Zacks Rank #1 (Strong Buy) List on October 31, 2025.
Company News for Oct 30, 2025
by Zacks Equity Research
Companies in The News Are: BA,VZ,CAT,CNC
Centene Q3 Earnings Beat Estimates on Increasing Premium
by Zacks Equity Research
CNC's Q3 earnings beat estimates as strong premium growth and rising membership in PDP and Marketplace units offset higher medical costs.
Centene (CNC) Reports Q3 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for Centene (CNC) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Centene (CNC) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Centene (CNC) delivered earnings and revenue surprises of +338.10% and +4.35%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Can Centene's Q3 Earnings Escape Industry's Cost Headwinds?
by Zacks Equity Research
CNC braces for Q3 results as revenue growth may be offset by rising medical costs and shrinking Medicaid memberships.
CVS Health's Aetna Advances Initiative to Curb Hospital Readmissions
by Moumi Mondal
CVS company, Aetna, expands its Aetna Clinical Collaboration program to 10 hospitals, aiming to cut readmissions and ease hospital workloads.
Centene Sits at 13.25X P/E: Time to Load Up or Look Away for Now?
by Kaibalya Pravo Dey
CNC's low 13.25X P/E may look attractive, but falling margins, heavy debt and shrinking memberships paint a tougher picture.
CVS Health Makes Headway in Stabilizing Aetna: What's Driving It?
by Moumi Mondal
CVS makes progress in stabilizing Aetna with leadership, risk management and operational changes.
Humana Wins TVH Assets in Bankruptcy Sale, But Cut Points Drag Shares
by Zacks Equity Research
HUM scoops up $68M Florida care centers, but star rating hurdles send shares tumbling 12%. Can HUM turn risk into reward?
UnitedHealth Finds Its Stars, Soars 8.6% as Humana Trips on Cut Points
by Kaibalya Pravo Dey
UNH surges 8.6% as it projects stable Medicare Advantage star ratings, easing investor worries over performance.
UnitedHealth Reaffirms 2025 EPS Guidance: Time to Buy or Wait?
by Kaibalya Pravo Dey
UNH reaffirms its 2025 EPS outlook, but mounting costs, legal probes and valuation pressures cloud the path ahead.
Cyberattack Hangover: Senators Question UnitedHealth's Loan Playbook
by Kaibalya Pravo Dey
Senators question UNH over tough loan repayment demands post-cyberattack, adding to regulatory and cost pressures.
Why Is UnitedHealth (UNH) Up 14.2% Since Last Earnings Report?
by Zacks Equity Research
UnitedHealth (UNH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Are Strategic Contracts and Partnerships Centene's Growth Engine?
by Tanuka De
Centene's growth hinges on government contracts and strategic partnerships, but shares have plunged over 52% this year.
Not Just Medicare, UnitedHealth's Optum Rx Gets Its Own DOJ Checkup
by Kaibalya Pravo Dey
UNH faces a widened DOJ probe, covering Optum Rx and physician payments, as rising medical costs pressure its business.
UnitedHealth's Misdiagnosis: Can Berkshire's Bet Spark a Recovery?
by Kaibalya Pravo Dey
Berkshire's $1.57B bet on UNH sparks investor interest, but soaring costs, weak earnings and legal woes still cloud recovery hopes.
Centene Faces HBR Pressures: Will Scale Support Stability?
by Tanuka De
CNC's rising HBR, driven by higher medical costs and policy shifts, pressures margins as it leans on scale and efficiency for stability.
Elevance Shoots for the Stars But Lands at 3.5: $375M Bonus Gone?
by Zacks Equity Research
Federal judge dismisses ELV's lawsuit challenging Medicare Advantage star ratings, leading to a $375M bonus loss tied to its star score.
CNC vs. HUM: Which Managed-Care Stock is a Smarter Investment?
by Tanuka De
Humana's strong Medicare Advantage growth and higher ROE give it an edge over Centene, which faces earnings pressure and OBBB Act headwinds.
Food as Medicine: Elevance Health & NACHC Integrate Nutrition in Care
by Zacks Equity Research
ELV partners with NACHC to bring Food as Medicine into primary care, targeting nutritional insecurities and chronic disease.
Buffett's Shot in the Arm Sends UnitedHealth Soaring Against the Odds
by Kaibalya Pravo Dey
Buffett's $1.57B bet on UNH sparks a 12% surge, lifting peers despite sector headwinds and recent struggles at the insurer.